Smith+Nephew is a global portfolio medical technology company that develops products for the repair, regeneration, and replacement of soft and hard tissue. Founded in 1856 and headquartered in Hull, England, the company operates in more than 100 countries and employs over 18,000 people. It is listed on the London Stock Exchange, where it is a FTSE 100 constituent, as well as the New York Stock Exchange.
The company's technical work spans several domains relevant to AI and advanced computing, including surgical robotics and biomaterials. Its CORI Surgical System is a robotics-assisted surgical platform used in orthopaedic procedures. Other key product lines include the REGENETEN Bioinductive Implant, designed for tissue regeneration, and the PICO negative pressure wound therapy system for wound care. These products sit at the intersection of hardware engineering, data-driven surgical planning, and materials science.
Smith+Nephew's broader technical domains include orthopaedics, sports medicine, ENT (ear, nose, and throat), and advanced wound management. The company serves millions of patients annually through its medical device and wound management businesses, operating across industry verticals that increasingly incorporate machine learning, computer vision, and robotics into clinical workflows.
